Working... Menu

Role of Mobile Technology to Improve Diabetes Care in Adults With Type 1 Diabetes: the REMOTE-T1D Study, a Pilot Study (REMOTE-T1D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01825382
Recruitment Status : Completed
First Posted : April 5, 2013
Last Update Posted : May 21, 2014
Colorado Prevention Center
Information provided by (Responsible Party):
Satish K. Garg, University of Colorado Denver School of Medicine Barbara Davis Center

Brief Summary:
The goal of this prospective pilot study is to evaluate the use of remote technology (iBGStar in combination with Diabetes Manager App on iPhone) to patient related outcomes, and a hypoglycemia fear questionnaire. In the future, this study might lead to investigating the role of social media with mobile phones in Type 1 Diabetes (T1D) care. Moreover, the number of patients with T1D continues to increase, and such technology could conceivably help compensate for the shortages of endocrinologists providing care.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Device: iBGStar meter Phase 4

Detailed Description:

This is a single-center, prospective, randomized, 'open-label,' investigator initiated pilot study evaluating the role of mobile technology to improve diabetes care in adults with type 1 diabetes (REMOTE-T1D). We hypothesize that the use of mobile technology (iBGStar® technology [iPhone® plus the BGStar®]) will result in improvement in Patient Reported Outcomes (PRO), and Treatment Satisfactions with a possible reductions of glucose excursions, A1c, and severe hypoglycemia as compared to routine clinical care using traditional glucose meter SMBG-Accu-chek®. This study aims to demonstrate the efficacy of these technologies in a clinical setting with a hope to improve outcomes and health care cost savings.

The study will enroll 100 patients from the Barbara Davis Center Adult clinic over the age of 18 years who will be randomized in a 1:1 fashion to intervention group using mobile technology (iBG Star) vs. continued routine clinical care (control) using SMBG-Accu-chek meter. All subjects will be followed for study visits with similar frequency at baseline, 1-week, 1-month, 3-months, and 6-months and wear a continuous glucose monitor (CGM) using a DexCom SEVEN Plus® system in a blinded mode for 7 days at baseline (wk0), 1mo, 3mo, and 6mo.

Laboratory analysis for A1c will be performed at baseline, 1-month 3-months, and 6-months. Routine blood tests will be performed in all subjects at baseline, 3months, and 6-months. Blinded CGM data will be analyzed for mean blood glucose values, time spent in hyperglycemic (>240, >300mg/dl) and hypoglycemic (<50, <70, <80 mg/dl) ranges and various indices of glycemic variability.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Role of Mobile Technology to Improve Diabetes Care in Adults With Type 1 Diabetes: the REMOTE-T1D Study, a Pilot Study
Study Start Date : December 2012
Actual Primary Completion Date : August 2013
Actual Study Completion Date : November 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
No Intervention: Accu-chek Meter
Patients receiving the Accu-chek nano meter for use during the study.
Experimental: iBGStar meter interventional Arm
Subjects are given iBGstar meter along with iPhone to use as interventional meter.
Device: iBGStar meter
Subjects will receive iBGStar meter and iPhone to use as meter during the study.

Primary Outcome Measures :
  1. Patient Reported Outcomes as it relates to hypoglycemia fear and quality of life. [ Time Frame: 6 months ]
    Primary outcome is patient related outcomes and changes based on the hypoglycemia fear questionnaire and changes in patient comfort in meter use.

Secondary Outcome Measures :
  1. Improvement in glucose control and indices off glucose variability from SMBG and CGM data. [ Time Frame: 6 months ]
    Improvement in parameters of glycemic variability as measured by glucose excursions from SMBG and CGM downloads and various indices (J-index, mean amplitude of glycemic excursion (MAGE), high blood glucose index (HBGI), low blood glucose index (LBGI), from, CGM downloads. Reduction in A1c of 0.3% from screening to 3-months and maintained at 6-months, and reduction of hypoglycemia (measured or self reported). Cost analysis will be done based upon primary and secondary outcomes.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects that meet the following criteria will be considered for admission to the study:

    1. Signed informed consent before any study-related activities
    2. Male or female aged 18 years and older T1D duration >1 year
    3. A1c <10%
    4. Willingness to routinely practice at least 3-7 blood glucose measurements per day
    5. Ability and willingness to adhere to the protocol including scheduled study visits and blinded CGM wear intermittently) for 6 months. During the weeks of blinded CGM wear, subjects will not be able to use their own real-time CGMs (if they own it)
    6. Able to speak, read and write English

Exclusion Criteria:

  • Subjects will be excluded from the study if any of the following apply:

    1. Pregnant or intention to become pregnant during the course of the study
    2. Severe unexplained hypoglycemia requiring emergency treatment in the previous 6 months
    3. Use of systemic or inhaled corticosteroids
    4. History of hemoglobinopathies
    5. Diagnosis of anemia
    6. History of pancreatitis
    7. Extensive skin changes/diseases that inhibit wearing a sensor on normal skin
    8. Known allergy to adhesives
    9. Current participation in another investigational study protocol. Must have completed a previous study at least 30 days prior to enrollment.
    10. Any other condition, as determined by the investigator, which could make the subject unsuitable for the trial, impairs the subject's suitability for the trial, or impairs the validity of the informed consent
    11. Subjects will not be allowed to use real-time CGM during the blinded CGM wear week.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01825382

Layout table for location information
United States, Colorado
Barbara Davis Center
Aurora, Colorado, United States, 80045
Sponsors and Collaborators
University of Colorado Denver School of Medicine Barbara Davis Center
Colorado Prevention Center
Layout table for investigator information
Principal Investigator: Satish K Garg, MD University of Colorado, Denver

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Satish K. Garg, Professor of Medicine and Pediatrics, Editor in Chief DT&T, University of Colorado Denver School of Medicine Barbara Davis Center Identifier: NCT01825382     History of Changes
Other Study ID Numbers: REMOTE-T1D
First Posted: April 5, 2013    Key Record Dates
Last Update Posted: May 21, 2014
Last Verified: May 2014

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases